Tekla Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Tekla Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$5.61M	Hold	176,483	–	–	0.22%	83
2023 Q1	$4.3M	Hold	176,483	–	–	0.16%	84
2022 Q4	$5.57M	Hold	176,483	–	–	0.21%	75
2022 Q3	$4.99M	Buy	176,483 +88,310	+100%	+$2.63M	0.2%	79
2022 Q2	$2.33M	Buy	88,173 +14,492	+20%	+$411K	0.09%	108
2022 Q1	$2.58M	Buy	73,681 +32,678	+80%	+$954K	0.09%	117
2021 Q4	$1.33M	Buy	+41,003	New	+$1.45M	0.04%	141

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Tekla Capital Management's CERE Position: Q2 2023 in Review

Tekla Capital Management held its Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) position steady in Q2 2023 at 176,483 shares worth $5.61M. The position accounts for 0.22% of the portfolio, ranked #83.

Tekla Capital Management first reported a position in CERE in Q4 2021 and has held it in 7 quarters since. 125 funds tracked by Wall St. Rank hold CERE as of Q2 2023.

Tekla Capital Management held 176,483 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $5.61M as of Q2 2023.
Tekla Capital Management left its Cerevel Therapeutics Holdings, Inc. Common Stock share count unchanged in Q2 2023.
Cerevel Therapeutics Holdings, Inc. Common Stock made up 0.22% of Tekla Capital Management's portfolio in Q2 2023, its #83 holding.
Tekla Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and has held it in 7 quarters since.
125 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.